Bio-Rad Laboratories SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit
Bio-Rad Laboratories has announced that its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA).
Running on Bio-Rad’s QX200 and QXDx ddPCR systems, the high sensitivity of the test makes it well suited to screening upper respiratory samples in patients with a low viral load, including individuals in the early stages of infection as compared to classical quantitative PCR tests. The test can also play an important role in surveillance by detecting minimal residual disease in people recovering from COVID-19, informing them if they are negative for the virus.
The single-well ddPCR test is said to provide clinicians with a high degree of sensitivity in detecting infection of COVID-19 at an early stage. It should thus serve as a powerful complement to current diagnostics, helping clinicians and public health officials identify infected individuals in a timely manner.
Phone: 02 9914 2800
Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium
The products provide researchers and manufacturers with high-performance, scalable and...
Grace Bio-Labs protein microarray tools
Grace Bio-Labs' microarray substrates provide high binding capacity and enable high assay...
Siemens Healthineers 3gAllergy assay
Siemens Healthineers has expanded its 3gAllergy assay menu with nine additional component...
